Centiva Capital, LP Ultragenyx Pharmaceutical Inc. Transaction History
Centiva Capital, LP
- $5.63 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding RARE
# of Institutions
287Shares Held
88.1MCall Options Held
505KPut Options Held
198K-
Vanguard Group Inc Valley Forge, PA9.78MShares$532 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$305 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA5.35MShares$291 Million0.68% of portfolio
-
Wellington Management Group LLP Boston, MA4.56MShares$248 Million0.03% of portfolio
-
Rtw Investments, LP New York, NY3.26MShares$177 Million2.24% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $3.81B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...